A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Summary

This is an open-label, randomized, multicenter, phase III study Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO Alfa 60000 UI/week for at least 12 weeks: * Either at diagnosis Or * at the Hb threshold chosen for RBC transfusions (must be \< 9g/dl)

Timeline

Start

2018-03-26

Primary completion

2023-09-21

Completion

2028-10-01

Drugs

Indications